Triple-Negative Breast Cancer

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Oncology in the Precision Medicine Era

• Publication date

  2019-12-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-030-31471-2_13
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract OT1-05-01: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer

  2018cited by this paper
• Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

  2018cited by this paper
• Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)

  2018cited by this paper
• AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

  2018cited by this paper
• IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC).

  2018cited by this paper
• Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS).

  2018cited by this paper
• Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA

  2018cited by this paper
• TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

  2018cited by this paper
• Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

  2018cited by this paper
• Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

  2018cited by this paper
• Abstract OT1-05-02: A phase II clinical trial of the combination of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor positive triple negative breast cancer

  2018cited by this paper
• OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).

  2017cited by this paper
• Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

  2017cited by this paper
• PARP inhibitors: Synthetic lethality in the clinic

  2017cited by this paper
• Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

  2017cited by this paper
• Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

  2017cited by this paper
• Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

  2017cited by this paper
• Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

  2017cited by this paper
• Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

  2017cited by this paper
• LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).

  2017cited by this paper
• 320TiPA phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC

  2017cited by this paper
• Triple-negative breast cancer: treatment challenges and solutions

  2016cited by this paper
• Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

  2016cited by this paper
• A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

  2016cited by this paper
• Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

  2016cited by this paper
• Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis

  2016cited by this paper
• Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes

  2016cited by this paper
• Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)(+) metastatic breast cancer (MBC): Pharmacokinetics (PK)

  2016cited by this paper
• Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC).

  2016cited by this paper
• The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

  2016cited by this paper
• Features of triple-negative breast cancer

  2016cited by this paper
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

  2015cited by this paper
• Subtyping of triple‐negative breast cancer: Implications for therapy

  2015cited by this paper
• Abstract OT1-1-16: A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)

  2015cited by this paper
• Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

  2015cited by this paper
• Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

  2015cited by this paper
• LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).

  2015cited by this paper
• A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC.

  2015cited by this paper
• TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

  2015cited by this paper
• Triple-negative breast cancer: molecular subtypes and new targets for therapy.

  2015cited by this paper
• Clinical implications of molecular heterogeneity in triple negative breast cancer.

  2015cited by this paper
• Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

  2014cited by this paper
• Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

  2014cited by this paper
• Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options

  2014cited by this paper
• Exomics and immunogenics

  2014cited by this paper
• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

  2014cited by this paper
• Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

  2014cited by this paper
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

  2014cited by this paper
• Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

  2014cited by this paper
• Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

  2013cited by this paper
• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

  2013cited by this paper
• Abstract P3-03-08: A comparison of PI3K inhibition by eribulin, other microtubule targeting agents and a DNA-damaging chemotherapeutic in triple negative and HER2 expressing breast cancer cell lines

  2013cited by this paper
• Molecular Pathways Molecular Pathways : PI 3 K Pathway Targets in Triple-Negative Breast Cancers

  2013cited by this paper
• Effect of eribulin on cell growth and PI3K pathway activity with and without RAD001 in triple-negative and HER2-expressing breast cancer.

  2013cited by this paper
• Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cells

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

  2012cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

  2011cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

  2011cited by this paper
• Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

  2010cited by this paper
• I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

  2009cited by this paper
• Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

  2009cited by this paper
• Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

  2009cited by this paper
• DNA repair pathways as targets for cancer therapy

  2008cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper

• “Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics”

  2021cites this paper